ADM + NPWT for Open Fractures: 7 Case Series | Medipyxis
Acellular Dermal Matrix + NPWT for Open Fractures: A Less‑Invasive Soft‑Tissue Reconstruction Pathway (7‑Case Series)
Medical education note: For clinicians; not a substitute for patient‑specific medical advice.
Clinician TL;DR
A single‑surgeon retrospective series (2022–2025) from Rutgers New Jersey Medical School evaluated meshed human reticular acellular dermal matrix (HR‑ADM) combined with negative pressure wound therapy (NPWT) for extremity wounds with periosteal stripping/exposed bone after open fractures and other severe injuries. Among 7 patients (mean age 57; 86% lower extremity; wounds 6–700 cm², median 48 cm²; 86% traumatic; 71% infected), all developed healthy granulation tissue over HR‑ADM; 4 proceeded to split‑thickness skin grafting (STSG) and 6/7 wounds (86%) were documented closed at follow‑up (two without grafting). One recent patient was still granulating at the time of reporting. [2, 9]
Why this matters
Open‑fracture soft‑tissue loss—especially with periosteal stripping—often pushes teams toward flap reconstruction, yet many patients are poor flap candidates due to comorbidities, contamination, or resource constraints. Aseptically processed, meshed HR‑ADM offers an open scaffold for host ingrowth and revascularization; when paired with NPWT, it can create a graft‑ready bed or even support secondary closure in select cases—offering a less‑invasive, staged alternative to immediate flap surgery. [2, 9]
What the Rutgers series did (and found)
Design & setting. Single‑surgeon, retrospective chart review (2022–2025) of extremity wounds with periosteal stripping treated with meshed HR‑ADM + NPWT; endpoints: granulation presence, receipt of STSG, and wound closure. [2, 9]
Population snapshot.
(A 57 year old patient with a chronic lower extremity wound.)
n = 7; mean age 57; 57% male
86% lower‑extremity wounds
Wound area 6–700 cm² (median 48 cm²)
86% traumatic; 71% infected at presentation
Outcomes.
(Same 57 year old patient post-op)
Healthy granulation documented in all wounds after HR‑ADM application
STSG performed in 4/7 (57%)
Closure achieved in 6/7 (86%), including 2 that closed without grafting
1 recent case: HR‑ADM placed with granulation in progress at last follow‑up
How the technique fits together
HR‑ADM (what it is). An aseptically processed meshed human reticular acellular dermal matrix with an open architecture that supports tissue in‑growth and revascularization—useful when bone/periosteum is exposed and flap options are limited or deferred. [2, 9]
NPWT (why pair it). Creates stable contact, manages exudate/bioburden, and helps mature granulation across irregular, deep, or contaminated beds—preparing for STSG when indicated. [8, 1]
The staged pathway (case‑series model).
Debridement to a clean, bleeding bed; treat infection early. [8, 1]
Apply meshed HR‑ADM over exposed structures. [2, 9]
Add NPWT to secure the matrix and manage the interface. [8, 1]
Reassess for granulation; proceed to STSG once graft‑ready—or continue toward secondary intention if progressing. [3, 6]
When to consider HR‑ADM + NPWT
Open fractures with periosteal stripping/exposed bone where flap is contraindicated or delayed. [3, 6]
Infected or contaminated wounds after adequate source control and debridement. [8, 1]
Large surface‑area defects where a granulation scaffold can reduce reconstructive complexity or stage toward STSG. [3, 6]
Practical protocol you can adapt (clinic & OR)
Bed prep & infection control
Serial, aggressive debridement, culture‑guided therapy, and meticulous hemostasis before matrix application. [8, 1]
Matrix placement
Lay meshed HR‑ADM to maximize contact with viable tissue; conform to voids/edges. [2, 9]
NPWT over the matrix
Use NPWT dressings to maintain uniform pressure and moisture balance (institutional settings vary; the series does not specify device parameters). [8, 1]
Decision point at granulation [3, 6]
If bed is robust and uniform → STSG (done in 57% of patients in this series). [7, 10]
If epithelialization is advancing → consider continued secondary intention (achieved closure in some cases).
Follow‑through
Edema control, nutrition, offloading, ROM, and smoking cessation; photograph and measure at each visit.
Limitations (keep expectations honest)
Small case series (n = 7), single surgeon, and variable follow‑up—no comparator arm, cost analysis, or standardized NPWT parameters reported. Authors call for larger, prospective studies to validate indications and refine protocols. [8, 1]
Clinician FAQ
Is HR‑ADM + NPWT a replacement for flaps?
Not categorically. It’s a staged, less‑invasive pathway that can bridge to STSG or closure when flap surgery is contraindicated or deferred. [2, 9]
How often did patients need grafts?
4 of 7 (57%) underwent STSG after granulation; two others closed without grafting. [3, 6]
Does it work in infected wounds?
In this series, 71% of patients presented with infection; after debridement and management, all still developed healthy granulation over HR‑ADM. [2, 9]
Where were the wounds?
86% were lower extremity; wound sizes ranged 6–700 cm² (median 48 cm²). [5, 1]
Checklist (print‑ready)
Open fracture/periosteal stripping with limited flap options [3, 6]
Serial debridement + source control achieved [8, 1]
Meshed HR‑ADM placed; NPWT applied over matrix [2, 9]
Weekly measurements/photos; track granulation uniformity [3, 6]
Proceed to STSG when graft‑ready or continue secondary intention [7, 10]
Optimize edema control, nutrition, offloading, ROM, smoking cessation
Bottom line for wound teams
When flap options are limited, meshed HR‑ADM + NPWT can bridge exposed bone to a graft‑ready bed and standardize staged closure in carefully selected open‑fracture wounds. Build your pathway around debridement, matrix + NPWT, and timely STSG—and document outcomes prospectively to grow the evidence base. [2, 9]
References
[1] Menn ZK et al. Acellular Dermal Matrix + NPWT as alternative to free tissue transfer in compromised patients (2012, PubMed) — https://pubmed.ncbi.nlm.nih.gov/21959551/
[2] MTF Biologics (Rutgers series) 2025 – Meshed HR‑ADM + NPWT for periosteal stripping/extremity wounds (case series PDF) — https://www.mtfbiologics.org/docs/default-source/sawc/2025/somagen_adm_final.pdf?sfvrsn=79031359_1
[3] Hsu KF et al. NPWT combined with artificial dermis over exposed bone/tendon (2021, PMC case series, n=65) — https://pmc.ncbi.nlm.nih.gov/articles/PMC8036026/
[5] Kim Y et al. NPWT for temporary management of open tibia fractures (2023, PMC review/series) — https://pmc.ncbi.nlm.nih.gov/articles/PMC10837575/
[6] Wounds‑UK 2025 analysis – Evidence for NPWT granulation over exposed bone/tendon — https://wounds-uk.com/journal-articles/critical-analysis-of-evidence-in-the-use-of-negative-pressure-wound-therapy-for-granulation-of-wounds-with-exposed-bone-and-tendon/
[7] Song X et al. Applying human ADM with STSG + NPWT bolster (2024, Adv Skin Wound Care) — https://journals.lww.com/aswcjournal/fulltext/2024/06000/application_of_human_acellular_dermal_matrix_with.13.aspx
[8] Kahveci R et al. NPWT for complex surgical wounds – review (2022, PMC) — https://pmc.ncbi.nlm.nih.gov/articles/PMC9748823/
[9] Zelen CM et al. Human reticular ADM supports rapid healing in DFU (2017, PubMed) — https://pubmed.ncbi.nlm.nih.gov/28272011/
[10] J Wound Care 2013 – Artificial dermis + NPWT + STSG for wounds exposing bone/tendon — https://www.magonlinelibrary.com/doi/pdf/10.12968/jowc.2013.22.12.708?download=true
